X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2023/12/01/2789289/0/en/Palvella-Therapeutics-and-Ligand-Pharmaceuticals-Expand-Strategic-Partnership-to-Accelerate-Phase-3-Development-of-QTORIN-rapamycin-for-Microcystic-Lymphatic-Malformations-and-Addi.html
https://www.globenewswire.com//news-release/2023/11/16/2781752/0/en/Palvella-Therapeutics-Announces-U-S-FDA-Breakthrough-Therapy-Designation-Granted-to-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-M.html
https://www.globenewswire.com/news-release/2023/07/20/2708226/0/en/Palvella-Therapeutics-Announces-Planned-Pivotal-Phase-3-Study-Design-of-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-Malformations.html
https://www.globenewswire.com/news-release/2023/03/09/2623986/0/en/Palvella-Therapeutics-Announces-Positive-Topline-Results-from-Phase-2-Study-of-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Microcystic-Lymphatic-Malfor.html
https://www.globenewswire.com/news-release/2023/02/21/2611988/0/en/Palvella-Therapeutics-Announces-Pipeline-Update-on-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-Rapamycin-for-Serious-Rare-Genetic-Skin-Diseases-with-No-FDA-approved-Therapies.html
https://www.globenewswire.com//news-release/2023/01/05/2584139/0/en/Palvella-Therapeutics-Announces-Series-D-Financing-of-Up-to-37-7-Million-to-Accelerate-Late-Stage-Development-and-Support-Commercialization-of-Novel-Therapies-for-Serious-Rare-Gene.html
https://www.globenewswire.com/news-release/2019/11/13/1946332/0/en/Palvella-Therapeutics-Commences-Phase-3-Portion-of-Phase-2-3-Pivotal-Study-of-PTX-022-in-Pachyonychia-Congenita.html
https://www.thepharmaletter.com/in-brief/brief-medpharm-and-palvella-expand-pachyonychia-congenita-partnership
https://www.contractpharma.com/contents/view_breaking-news/2019-02-11/medpharm-palvella-expand-partnership
Market Place
Share 
